Form 144 Hims & Hers Health, Inc. Filed by: Chi Michael
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- European shares subdued as surging crude sharpens focus on ECB rate path
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Alibaba (BABA) PT Lowered to $165 at Bernstein SocGen Group
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
February 21, 2025 12:23 PM ESTPiper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More
Why Morgan Stanley is cautious on Hims & Hers shares
February 20, 2025 4:00 PM ESTMorgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the companys latest move into at-home lab testing through its acquisition of Trybe Labs.
The investment bank maintains an Equal-weight rating on the stock, arguing that excitement around the companys growth potential may be outpacing realistic financial... More
Hims and Hers (HIMS) PT Raised to $21 at BofA Securities
February 20, 2025 5:18 AM ESTBofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $21.00 (from $18.00) while maintaining a Underperform rating.
The analyst comments "HIMS observed sales per Bloomberg Second Measure (BSM) data grew 104% y/y in January and suggests GLP-1s... More
